• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Monday 07/23/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIDS

  • 5:01 PM

    VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily treatment-experienced HIV-1 patients will be presented in a Late-Breaker Abstract poster session at ASM Microbe on Saturday, June 9, in Atlanta.  The trial results detail data from the one-week, single-dose, randomized, double-blind, placebo-controlled portion of the pivotal trial of PRO140 in combination with optimized background anti-retroviral therapy (ART). Session 226: Late

    Read more
  • 10:45 AM

    Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY) announces that results from its CD01 Phase 2b clinical trial and extension study showing the potential of PRO 140, its novel humanized CCR5 monoclonal antibody, as a long-acting, single-agent maintenance therapy for HIV-1 infected patients were published in the peer-reviewed journal HIV Clinical Trials. All HIV-1 infected patients enrolled in the CD01 Phase 2b trial exhibited suppressed viral load

    Read more
  • 8:16 AM

    ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, is pleased to announce that the Kenya Pharmacy and Poison Board filed IMUN’s New Drug Application (NDA) for Lodonal™, its lead drug candidate, thereby accepting the NDA for a full review. Kenya is experiencing an HIV

    Read more
  • 1:55 PM

    ORLANDO, Fla., Sept. 06, 2017, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases and other inflammatory conditions, today announced that it has entered into an exclusive agreement with Kenya-based Omaera Pharmaceuticals, Ltd. for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d02d7135-cf47-471f-9fa0-17fa3e9728a7. Under the

    Read more
  • 2:35 PM

    ORLANDO, Fla., May 19, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( ” WHA ” ) in Geneva, Switzerland to promote LodonalTM. The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member

    Read more
  • 2:26 PM

    ORLANDO, Fla., April 27, 2016, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. The receipt of NAFDAC’s approval will enable the

    Read more
Public Wire Banner